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Abstract Introduction: The ability of staphylococci to produce biofilm is an important virulence mechanism that 
allows bacteria both to adhere and to live on artificial surfaces and to resist to the host immune factors and 
antibiotics. Staphylococcal infections have become increasingly difficult to treat due their antibiotic resistance. 
Therefore, there is a continuous need for new and effective treatment alternatives against staphylococcal 
infections. The main goal of this study was to test N-acetylcysteine (NAC) and vancomycin alone and in 
combination against S. epidermidis and S. aureus biofilms. Methods: Biofilms were treated with NAC at 
minimum inhibitory concentration (MIC) and 10 × MIC concentrations and vancomycin at MIC and peak 
serum concentrations. Results: The use of NAC 10 × MIC alone showed a significant antibactericidal 
effect, promoting a 4-5 log10 CFU/ mL reduction in biofilm cells. The combination of NAC 10 × MIC with 
vancomycin (independently of the concentration used) reduced significantly the number of biofilm cells for 
all strains evaluated (5-6 log10). Conclusion: N-acetylcysteine associated to vancomycin can be a potential 
therapeutic strategy in the treatment of infections associated to biofilms of S. epidermidis or S. aureus.
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Introduction
Staphylococci are the most frequent causative agents 
of nosocomial infections and infections on medical 
devices (Otto, 2008). Their ability to form biofilm on 
surfaces, either biotic or abiotic, seems to be critical 
for the establishment of infections and to contribute 
to their persistence by protecting cells from antibiotics 
and host defenses (Costerton et al., 1999; Domínguez-
Herrera et al., 2012; Mah and O’Toole, 2001). 
S. epidermidis is able to form biofilms on implanted 
medical devices namely central venous catheter, 
urinary catheters, prosthetic heart valves, orthopedic 
devices, contact lenses, being also responsible by 
chronic infections such as septicemia and endocarditis 
(Cargill and Upton, 2009). Staphylococcus aureus has 
been recognized as a common cause of human disease 
(Lowy, 1998) and, as in the origin of a wide range 
of infections, from minor skin infections, chronic 
bone infections until to devastating septicemia and 
endocarditis (Chambers, 2005; Charles et al., 2004; 
Davis, 2005; Gosbell, 2005; Howden et al., 2004). 
S. aureus are also associated with infections related 
to artificial devices (Cramton and Gotz, 2004).
Biofilm formation is nowadays seen as the main 
virulence mechanism evidenced by staphylococci. 
The presence of polymeric matrix in biofilms is 
preponderant to bacterial adhesion and produces 
a complex structure that makes the eradication of 
microorganisms more difficult (Boles and Horswill, 
2011; Kloos and Bannerman, 1994). Bacterial biofilms 
are difficult to detect in routine diagnostics and are 
inherently tolerant to host defenses and conventional 
antibiotic therapies (McCann et al., 2008). Additionally, 
the emergence of antibiotic-resistant bacteria and 
the slow progress in identifying new classes of 
antimicrobial agents have encouraged research into 
novel therapeutic strategies (Costerton et al., 2009). 
One of the approaches to solve this problem is the 
use of antimicrobial agent combinations because the 
development of resistance is reduced when drugs are 
combined (Blaser et al., 1995; Chuard et al., 1991; 
Gagnon et al., 1992; Lucet et al., 1990).
Moreover, combinatorial therapies are used with the 
aim of find a more effective alternative to antibiotics 
alone since combinations may allow the enhancement 
of the effects of individual antimicrobial agents by 
synergistic action.
N-acetylcysteine (NAC) is a non-antibiotic drug 
that has antibacterial properties (Perez-Giraldo et al., 
1997). NAC affects several processes that are important 
for bacterial biofilm formation on stainless steel 
surfaces, including a drastic reduction in extracellular 
polysaccharide production, and thus acts as an 
antibiofilm substance (Olofsson et al., 2003). On 
the other hand, vancomycin is a glycopeptide that 
inhibit cell wall synthesis of S. aureus and other 
Gram-positive organisms (Pootoolal et al., 2002). 
Then, the aim of this work was to determine the in 
vitro effect of two antimicrobial agents with different 
mode of action, alone and in combination, against 
biofilms of S. epidermidis and S. aureus.
Methods
Bacterial strains and growth conditions
S. epidermidis (5 strains- 1, 127, 165, 9142 and 1457) 
and S. aureus (5 strains- 2, 35, 73, 173 and 174) 
clinical isolate strains were used in this study. The 
culture media used (tryptic soy broth (TSB), tryptic soy 
agar (TSA) and Mueller-Hinton agar) were prepared 
according to the manufacturer instructions. All strains 
were inoculated into 15 mL of TSB from TSA plates 
not older than 2 days and grown for 18 (± 2) h at 37 °C 
in an orbital shaker at 130 rpm. Cells were harvested 
by centrifugation (for 5 min at 9500 g and 4 °C), and 
ressuspended in TSB adjusted to 0.5 McFarland scale 
equivalent to 1.5 × 108 cells/mL–1 before being used 
in the subsequent assays. Each solution of NAC (MIC 
and 10 × MIC) was prepared in TSB and the solution 
of vancomycin (MIC and peak serum (Cerca et al., 
2005)) was prepared in Milli-Q water.
Vancomycin MIC determination: E test
The E test was used to evaluate the susceptibility of 
all staphylococci strains tested to vancomycin. The 
cell suspension (1.5 × 108 cells/mL), prepared with 
S. epidermidis or S. aureus, was applied with a sterile 
cotton swab onto Petri plates containing Mueller-
Hinton agar. The antibiotic carriers (E test strip) were 
then applied to each plate. Plates were incubated at 
37 °C for 24 h. After incubation, an elliptical zone 
of growth inhibition was seen around the strip. The 
MIC was read from the scale at the intersection of 
the elliptical zone with the strip.
N-acetylcysteine MIC determination: 
Microbroth dilution method
For all strains of staphylococci, the N-acetylcysteine 
MIC determination was carried out in a dilution range 
of 0.5-64 mg/mL. The MIC was determined in 96 well 
tissue culture plates (Sarstedt, Newton, NC, USA) 
containing 100 µL of a stock solution of NAC diluted 
with TSB and by adding at the end 100 µL of a cell 
suspension (1 × 106 cells mL–1). Plates were incubated 
at 37 °C with orbital shaking at 130 rpm for 24 h. After 
incubation the minimum inhibitory concentration was 
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determined by identifying the lowest concentration 
able to inhibit bacterial growth. The controls were 
cells not exposed to the antimicrobial agent tested. 
All experiments were carried out in triplicate and 
repeated three times.
Congo red agar test
The Congo red agar is made up of brain heart infusion 
broth 37 g/L, sucrose 50 g/L, agar 10 g/L and Congo 
red dye 0.8 g/L. All cell suspensions (1.5 × 108 cells/
mL) were seeded separately on plates containing 
the Congo red agar. Plates were incubated at 37 °C 
for 24 h. After incubation, the staphylococci that 
produced black colonies were considered positive 
slime producers, whereas the colonies that showed 
red color were considered negative.
Expression of gene icaD
Isolation of genomic DNA
S. epidermidis and S. aureus chromosomal DNA 
was extracted with Invitek® kit (Uniscience, Brazil).
Polymerase chain reaction-PCR
The primers used for the amplification of icaD genes 
were designed from the published sequence of the ica 
locus described by Cramton and Gotz (2004). For the 
detection of icaD, primers iCADF (ATG GTC AAG 
CCC AGA CAG AG) and iCADR (CGT GTT TTC 
AAC ATT TAA TGC AA) were used for a 198 bp 
fragment. A 20 µL reaction volume consisted of 
2.5 mM MgCl2, 200 mM of each nucleotide, 1 mM 
of each primer, 1.25 U of Taq polymerase and 100 ng 
of template DNA. Thirty cycles of amplification, each 
consisting of denaturation at 92 °C for 45 s, annealing 
at 49 oC for 45 s and elongation at 72 °C for 1 min, 
along with a final extension at 72 °C for 7 min were 
performed in a thermocycler (Eppendorf, USA). The 
presence and size of the amplified products were 
confirmed by electrophoresis on 1.5% agarose gel.
Effect of NAC and vancomycin on bioﬁlm 
cells
Biofilms were formed in 96 well tissue culture plates 
(Sarstedt, Newton, NC, USA) containing 200 µL of a 
cell suspension (1 × 106 cells/mL) in TSB supplemented 
with 0.25 % of glucose per well to promote biofilm 
formation. Plates were incubated at 37 °C with orbital 
shaking at 130 rpm for 24 h. At the end, planktonic 
cells were removed carefully, and the biofilm was 
washed twice with 200 µL of saline solution (0.9% 
NaCl; Merck). The biofilms were incubated for 24 h 
in fresh nutrient medium containing NAC (MIC and 
10 × MIC) and vancomycin (MIC and peak serum) 
alone and in combination.
To assess the number of viable cells after treatment, 
200 µL of saline solution were added to each well 
before removing the biofilm by scrapping. An aliquot 
of 1 mL of each sample was centrifuged (for 10 min 
at 9500 g and 4 °C) and the pellet ressuspended in 
1 mL of saline solution. Next, the suspension was 
sonicated (20 s with 22% of amplitude; Ultrasonic 
Processor, Cole-Parmer, Illinois, USA) to promote 
biofilm disruption. The number of colony forming 
units (CFU) in biofilm for each strain evaluated was 
determined by performing 10-fold serial dilutions in 
saline solution and plating in TSA in triplicate and 
incubating for 48 h.
Biofilm controls were cells not exposed to any 
antimicrobial agent tested. All experiments were 
carried out in triplicate and repeated three times.
Statistical Analysis
The data from all assays were compared using one-
way analysis of variance (ANOVA) by applying 
Tukey’s test with all calculations carried out using 
SPSS software (Statistical Package for the Social 
Sciences). Differences achieving a confidence level 
of 95 % were considered significant.
Results
Table 1 summarizes the values of vancomycin 
minimum inhibitory concentration obtained by E 
test and NAC minimum inhibitory concentration 
determined by the microbroth dilution method, for all 
the strains of staphylococci tested in this study. On the 
other hand, Table 2 shows the production of slime by 
Congo red agar and the expression of icaD gene in the 
strains of staphylococci evaluated. Slime production 
was detected in three strains (60 %) of S. epidermidis 
and in all S. aureus strains (100 %). The icaD gene 
was expressed in all strains of staphylococci evaluated.
Figures 1 and 2 present the number of viable 
cells (after exposure to the two antimicrobial agents 
tested alone) of S. epidermidis and S. aureus strains 
tested, respectively, expressed as log CFU/mL. The 
results evidenced that vancomycin alone causes no 
effect on the staphylococci strains evaluated, since 
the reduction promoted by this antibiotic was less 
than 3 log10. On the contrary, the use of NAC alone 
showed to reduce the number of cells in biofilms of 
staphylococci strains. In fact, the use of NAC 10 × MIC 
reduced significantly the cells in biofilm, evidencing 
a reduction of circa of 4-5 log CFU/mL (p < 0.05).
Figures 3 and 4 present the number of viable 
cells (after the treatment with the two agents in 
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Table 1. Values of minimal inhibitory concentration by E test (vancomycin) and microbroth dilution method (MBD) (NAC) for the 
staphylococci strains studied.
Strains Number of laboratory identification E test (vancomycin) MBD (NAC)
S. epidermidis 9142 8 mg/mL 4 mg/mL
1457 8 mg/mL 4 mg/mL
1 3 mg/mL 8 mg/mL
127 4 mg/mL 8 mg/mL
165 3 mg/mL 8 mg/mL
S. aureus 2 2 mg/mL 8 mg/mL
35 2 mg/mL 8 mg/mL
73 1.5 mg/mL 8 mg/mL
173 2 mg/mL 8 mg/mL
174 2 mg/mL 8 mg/mL
Figure 1. Effect of NAC and vancomycin (VAN) alone on biofilm cells of S. epidermidis. *Antimicrobial effect statistically different from 
untreated cells (p < 0.05).
Figure 2. Effect of NAC and vancomycin (VAN) alone on biofilm cells of S. aureus. *Antimicrobial effect statistically different from 
untreated cells (p < 0.05).
Rev. Bras. Eng. Biom., v. 29, n. 2, p. 184-192, jun. 2013
Braz. J. Biom. Eng., 29(2), 184-192, June 2013 187
Leite B, Gomes F, Melo P, Souza C, Teixeira P, Oliveira R, Pizzolitto E
Figure 3. Effect of NAC and vancomycin (VAN) in combination on biofilm cells of S. epidermidis. *Combinations statistically different 
from control (p < 0.05).
Figure 4. Effect of NAC and vancomycin (VAN) in combination on biofilm cells of S. aureus. *Combinations statistically different from 
control (p < 0.05).
Table 2. Slime production determined by the method of Congo red agar and icaD gene expression.
Strains Number of laboratory identification Congo red agar(black or red colonies)
Gene expression of icaD
(present or absent)
S. epidermidis 9142 Black Present
1457 Black Present
1 Red Present
127 Black Present
165 Red Present
S. aureus 2 Black Present
35 Black Present
73 Black Present
173 Black Present
174 Black Present
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combination) of S. epidermidis and S. aureus strains 
tested, respectively, expressed as log CFU/mL. It can 
be observed that the combination of NAC at 10 × MIC 
with vancomycin (independently of the concentration 
used) showed a notorious effect on biofilm cells of 
all strains of S. epidermidis and S. aureus evaluated, 
promoting CFU reductions of about 5-6 log10 (p < 0.05).
Discussion
Bacterial cells have grown in biofilm for billions of 
years, as a part of their successful strategy to colonize 
most of this planet and most of its life forms. In fact, 
this is the predominant mode of growth of bacteria in 
natural environment. Their distinct phenotype makes 
them resistant to antimicrobial agents, and their matrix 
makes them tolerant to the antibacterial molecules 
and immune system cells mobilized by the host. 
The antimicrobial molecules must diffuse through 
the biofilm matrix in order to inactivate the encased 
cells. Thus, the extracellular polymeric substances 
constituting this matrix present a diffusional barrier 
for these molecules by inﬂuencing either the rate 
of transport of the molecule to the interior of the 
biofilm or the reaction of the antimicrobial agent with 
the matrix material (Donlan and Costerton, 2002; 
Presterl et al., 2009).
The ability of staphylococci cells to adhere and 
form biofilm is mediated by the production of the 
polysaccharide intercellular adhesin (PIA). Their 
synthesis is encoded by the gene product of ica 
locus of the operon icaADBC, being the product 
of this locus essential for biofilm formation and 
virulence of microorganisms (O’Toole et al., 2000). 
Arciola et al. (2001) work corroborates with the 
former statement, showing in their studies that the 
gene icaA and icaD have an important role in biofilm 
formation of S. epidermidis and S. aureus. The icaD 
gene was evaluated in this study and was reported to 
be expressed in all strains of S. epidermidis (100%) 
and S. aureus (100 %) evaluated. Another indicator 
of virulence is the Congo red reaction that provides 
information about the ability of microorganisms to 
produce slime (Prpic et al., 1983; Bernardi et al., 
2007). This study showed that three S. epidermidis 
strains (9142, 1457 and 127) and all S. aureus strains 
evaluated were slime producers.
Several authors have reported that the development 
of resistance is reduced when antibiotics are combined 
(Moellering, 2008; Perlroth et al., 2008). Taking into 
consideration this notion and aiming to overcome 
the current problem of the emergence of resistance 
several researchers focused their studies in the use of 
combinations. This study evaluated the susceptibility 
of biofilm cells of S. epidermidis and S. aureus to 
NAC and vancomycin alone and in combination. NAC 
was choose due to its potential role in biofilm matrix 
being able to reduce the extracellular polysaccharide 
content of biofilm (Olofsson et al. 2003). Our results 
demonstrated that NAC-vancomycin exhibited a 
significant antimicrobial effect on biofilm cells of 
all strains studied. This was possibly due to the 
degradation of the matrix promoted by NAC which 
facilitated the penetration into the biofilm and the 
action of vancomycin being then able to reduce 
the viable number of bacterial cells (Dunne et al., 
1993; Wilcox et al., 2001). As we have previously 
hypothesized this combination has a synergistic effect 
due to their different modes of action, acting into two 
different components of the biofilm namely the matrix 
and the cellular content. The use of vancomycin alone 
was ineffective against biofilm cells of the isolates 
studied, whereas NAC demonstrated a significant 
inhibitory action expressed by reductions of viability 
of circa of 4-5 log10 CFU/mL (Figures 1 and 2). As 
described by several authors, antibiotics at MIC 
concentration cause no killing effect on bacteria 
when growing in biofilm communities (Tetz et al., 
2009). Our results are in accordance with the previous 
researchers since NAC and vancomycin alone or 
in combination both at MIC concentration caused 
no killing effect on staphylococci cells, showing 
a viable cells reduction of less than 3 log10. On the 
contrary, when exposed to NAC-vancomycin (NAC 
10 × MIC combined with vancomycin independently 
of the concentration used) a high antibactericidal 
activity was observed, reaching a reduction on 
viability cells of about 5-6 log10 CFU/mL. Other 
studies were performed with the objective to find new 
therapeutic strategies using combinatorial approaches 
and using NAC or vancomycin but no promising 
results were obtained. As example, Gomes and co-
workers demonstrated that no synergy was observed 
combining farnesol with vancomycin (Gomes et al., 
2011) and NAC with farnesol (Gomes et al., 2012) 
on biofilms of S. epidermidis. The combination of 
NAC and tigecycline on S. epidermidis biofilms 
was reported by Aslam et al. (2007) and using 
NAC at 20 × MIC (80 mg/mL) and tigecycline at 
1000 × MIC (1 mg/mL), neither synergy nor an 
effective activity was also observed (reduction of 
less than 3 log10). On the other hand and supporting 
our results Abbas et al. (2012) studied the effect of 
NAC on biofilm cells of P. aeruginosa and showed 
that NAC has a moderate effect against this pathogen. 
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Zhao and Liu (2010) also proved the inhibitory effect 
of this compound against the previous microorganism 
expressed by the antibacterial activity and detachment 
of biofilm cells and defend that its action is caused by 
competitively inhibiting cysteine utilization in bacteria 
or by reaction of its sulfhydryl group with bacterial 
cell proteins. El-Feky et al. (2009) investigated the 
effect of NAC (2 and 4mg/mL) in combination with 
ciproﬂoxacin (MIC and 2 × MIC) against biofilm cells 
of several bacteria including S. aureus, S. epidermidis, 
E. coli. and others. The authors concluded that NAC 
potentiate the therapeutic action of ciproﬂoxacin. 
This was due to the ability of NAC to degrade the 
extracellular polysaccharide matrix of biofilms. As 
general conclusion they suggest the potential use of 
ciproﬂoxacin-NAC combination as therapeutic strategy 
against bacterial infections mediated by biofilms.
In general, it is believed that NAC is able of acting 
at the level of the matrix promoting the increasing 
therapeutic efficacy of vancomycin, which alone 
had no significant effect on cells in biofilms. This 
activity of NAC can result in the detachment of cells, 
individually or in clusters, becoming the biofilm and 
detached cells more susceptible to the action of other 
antimicrobial agents and to the immune system. 
Thus, the role of NAC and other antimicrobial agents 
targeting matrix and promoting this mechanism of 
detachment of cells can be an important help in the 
eradication of biofilms associated infections.
In conclusion, the results of the present study show 
excellent activity in vitro of NAC (10 × MIC) alone 
and in combination with vancomycin (MIC or peak 
serum) on S. epidermidis and S. aureus biofilms. The 
results indicate that this combination may represents 
a novel therapeutic option for infections caused by 
staphylococci, especially by strains able to form 
biofilm on biotic or abiotic surfaces, because the use 
of antimicrobial agents in combination as described by 
other authors reduces the development of resistance.
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